Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Specialty Chemicals
Allostery-focused Black Diamond launches
by Lisa Jarvis
December 16, 2018
| A version of this story appeared in
Volume 96, Issue 49
Black Diamond Therapeutics has emerged from stealth with $20 million from Versant Ventures to develop drugs targeting allosteric mutations that drive cancer. While industry has successfully developed drugs to block cancer-causing kinase mutations, mutations in allosteric sites—pockets outside a protein’s active site—have gone largely unexplored. Black Diamond, which is the first company to spring out of Ridgeline, one of Versant’s four biotech incubators, is first pursuing small molecules that target EGFR and HER2 allosteric mutants.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X